NeoGenomics, Inc
NeoGenomics is a U.S.-based cancer diagnostics company that provides oncology testing and consultative pathology services to help clinicians identify, classify, and monitor cancer. It operates a network of cancer-focused laboratories in the United States and the United Kingdom and also serves pharmaceutical customers with clinical trial testing, biomarker analysis, and oncology data solutions.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueDiagnostic laboratory testing used by physicians to detect, classify, and monitor cancer.
Next-generation sequencing and molecular assays used for therapy selection and disease characterization.
Minimal residual disease testing used to detect very low levels of cancer after treatment.
Physician and molecular expert review of laboratory results, including second-opinion pathology.
Laboratory testing, biomarker analysis, and study support for sponsor-led clinical research.
Licensing of de-identified oncology data to pharma and biotech customers for research and targeting.
Products
Reported · share of revenue- Client Direct Billing71.3 %
- Commercial Insurance16.2 %
- Medicare and Other Governmental12.5 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
NeoGenomics sells primarily to healthcare providers that need specialized cancer testing and expert interpretation, including community oncology practices, hospitals, pathology labs, reference labs, and academic centers. It also serves pharmaceutical and biotech sponsors that need biomarker testing, sample analysis, and data support for oncology drug development and clinical trials. The company’s value proposition is speed, breadth of oncology test menu, and consultative support for complex cases.
Buy routine and advanced cancer tests, MRD assays, and consultative support to manage patients locally.
Use NeoGenomics for specialized reference testing, complex case review, and overflow capacity.
Send difficult specimens for advanced molecular testing and expert interpretation.
Buy specialized oncology diagnostics for complex cases, research, and precision medicine programs.
Purchase lab services, biomarker analysis, and oncology data for clinical trials and drug development.
Strategy
NeoGenomics is focused on expanding share in oncology diagnostics through new tests, especially therapy selection and MRD, while improving the customer experience and operational efficiency. The company is also pushing deeper into community oncology and using partnerships, sales coverage, and data-driven services to broaden its reach. Its strategy combines product innovation with service differentiation to defend pricing and win more complex cases.
New therapy-selection and MRD assays support higher-value testing and strengthen the oncology menu.
Community oncology is a key growth channel where broad menus and service quality can win share.
Automation and platform upgrades can improve turnaround times, margins, and retention.
Sponsor services and data licensing diversify revenue beyond routine clinical testing.
Geography
NeoGenomics operates mainly in the United States, where most testing, sales, and customer relationships are concentrated. It also has a laboratory presence in Cambridge, United Kingdom, and receives some samples and data from outside the U.S., creating limited but real international compliance exposure. Geography matters because the business depends on specimen logistics, local lab capacity, and healthcare privacy rules across jurisdictions.
Risks
NeoGenomics faces execution risk from rapid scientific change, capacity constraints, and the need to keep launching relevant tests in a competitive market. Its business is also exposed to reimbursement pressure, regulatory scrutiny in healthcare referrals and privacy, and operational disruption from cyberattacks or lab system failures. Goodwill and intangible asset impairment is another meaningful risk because acquisitions have created large balance-sheet estimates tied to future performance.
- Competition and price pressureImpact: HighLikelihood: High
The company competes with large reference labs and CROs, which can pressure pricing and win rates.
Exposure: Clinical oncology testing and pharma services
- Technology obsolescenceImpact: HighLikelihood: High
The company must continually develop or license new testing technologies to stay relevant.
Exposure - Goodwill and intangible asset impairmentImpact: HighLikelihood: High
Acquisition-related assets depend on future cash flows and can be written down if assumptions weaken.
Exposure: Acquired businesses and intangibles
- Capacity constraintsImpact: HighLikelihood: Medium
If lab throughput or staffing cannot keep pace with demand, growth and service levels can suffer.
Exposure: Laboratory operations and turnaround times
- Cybersecurity and IT disruptionImpact: HighLikelihood: Medium
Lab operations depend on LIMS, CRM, and data systems; outages can halt testing and billing.
Exposure - Regulatory and privacy complianceImpact: MediumLikelihood: Medium
Healthcare referral laws, HIPAA, and GDPR can create penalties and operational restrictions.
Exposure: U.S. and U.K./EU data and clinical workflows
Accounting
Judgemental itemsClinical lab revenue depends on payer adjudication, contract terms, and collection timing.
Impact: Can affect reported revenue, bad debt, and cash conversion
Acquisition-related assets are tested against future cash flow assumptions and market conditions.
Impact: Can create large non-cash charges to earnings
A meaningful portion of operating expense is equity-based and affects comparability.
Impact: Reduces reported profit without immediate cash outflow
Recent acquisitions add one-time expenses that can obscure underlying operating trends.
Impact: Affects adjusted EBITDA and GAAP margin comparisons
Purchased technology and customer relationships are amortized over time.
Impact: Reduces operating income and net income
Similar listed companies
Publicly listed companies with a comparable business focus.
Nuvectis Pharma, Inc.
NVCT · Pharmaceutical Preparations
Myriad Genetics, Inc
MYGN · In Vitro & In Vivo Diagnostic Substances
Myriad Genetics develops and commercializes molecular diagnostic tests that help clinicians assess disease risk, guide treatment selection, and support earlier…
Neogen Corporation
NEOG · In Vitro & In Vivo Diagnostic Substances
Neogen Corp develops and sells products and services used to test food, feed, and agricultural inputs for safety and quality, while also providing genomics and animal safety solutions.
NeOnc Technologies Holdings, Inc
NTHI · Pharmaceutical Preparations
Fulgent Genetics, Inc.
FLGT · Services-Medical Laboratories
Biodesix, Inc
BDSX · Services-Medical Laboratories
Biodesix is a U.S.-based diagnostic solutions company focused on lung disease testing and diagnostic development services.
Last updated: 24/09/2026